How To Fight Against Resistant SuperBugs

British biopharma firm Helperby Therapeutics, a spin-out drug discovery company from St George’s University of London, has developed a novel answer to the clear and present danger of antimicrobial resistanceAntibiotic Resistance Breakers (ARBs). Doctors increasingly rely on last resort antibiotics such as carbapenems and colistin, but as harmful bacteria continue to mutate, this final line of resistance will eventually failHelperby’s solution to this critical problem, and ground-breaking innovation, is Antibiotic Resistance Breakers – novel technology that rejuvenates existing antibiotics into long-term effective combination therapies.

The World Health Organization (WHO) has identified the immediate threat from three critical priority pathogens for which there is currently limited antibiotic protection:

  • CRE (Carbapenem-resistant Enterobacteriaceae)
  • Pseudomonas aeruginosa(Carbapenem-resistant)
  • Acinetobacter (Carbapenem-resistant)

The most dangerous bacteria are CRE, causing severe and often fatal infections such as septicemia and pneumonia.CRE has spread from Asia into Europe and the USA, is epidemic and doubles every two years. 

Helperby’s Antibiotic Resistance Breakers rejuvenate existing antibiotics, enabling them to puncture the tough cell wall of CRE and other evolving superbugs to allow existing last-resort antibiotics to effectively do their work. The ARB rejuvenation process can be performed repeatedly on different combinations of existing antibiotics to outsmart resistance.

CLICK ON THE IMAGE TO ENJOY THE VIDEO

New classes of antibiotics are difficult to develop, and none have been marketed for over 30 years,” said Prof Anthony Coates, chief scientific officer of Helperby Therapeutics. “It is therefore imperative we keep existing antibiotics working. We are one of only six companies in the world that have new antibiotics in clinical development which are potentially effective against all three of WHO’s critical priority pathogens,” he added.

ARBs are novel, effective and transferable, potentially producing many variants of new antibiotic combination. One ARB can be applied to multiple different classes of antibiotics, reducing the size, time and resource in Phase III clinical trials normally required for new chemical entities.

Source: https://www.thepharmaletter.com/

Comments are closed.